CTCs detected in a blood sample from a liver cancer patient.

<p>A total of 10 CTCs were detected in this sample; 3 single migratory biophenotypic epithelial/mesenchymal CTCs, 3 single migratory mesenchymal CTCs and a tumor microembolus containing 4 mesenchymal CTCs were observed (epithelial biomarkers are indicated by red fluorescence; mesenchymal biomarkers are indicated by green fluorescence).</p

Calibration curve obtained using the optimized CanPatrol CTC enrichment technique in the spiking experiment (n = 8) using HepG2 cells at different dilutions.

<p>Calibration curve obtained using the optimized CanPatrol CTC enrichment technique in the spiking experiment (n = 8) using HepG2 cells at different dilutions.</p

Information and clinical characteristics of the patients.

<p>Information and clinical characteristics of the patients.</p

The three blood samples containing CTM from liver, nasopharyngeal and breast cancers.

<p>The three blood samples containing CTM from liver, nasopharyngeal and breast cancers.</p

EpCAM, CK8/18/19, vimentin and twist expression in HepG2 tumor cells and leukocytes.

<p><b>A</b>: negative control, leukocytes stained for CD45 expression (bright blue fluorescence); <b>B</b>: HepG2 cells stained for EpCAM expression (red fluorescence); <b>C</b>: HepG2 cells stained for CK8 expression(red fluorescence); <b>D</b>: HepG2 cells stained for CK18 expression(red fluorescence); <b>E</b>: HepG2 cells stained for CK19 expression(red fluorescence); <b>F</b>: HepG2 cells stained for vimentin expression (green fluorescence); <b>G:</b> HepG2 cells stained for twist expression(green fluorescence); <b>H:</b> HepG2 cells stained for EpCAM, CK8/18/19, vimentin and twist expression (red/green fluorescence). The cells were analyzed using a 100x oil objective</p

Additional file 5: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Figure S1. Migration and invasion assays of the five PCa cell lines. (A–B) Representative images and statistical comparison between PC-3 M 2B4 and PC-3 M 1E8 cells in wound healing (A, 100×) and Transwell (B, 200×) assays. (C–D) Representative images and statistical comparison among LNCAP, PC-3, and DU145 cells by wound healing (C, 100×) and Transwell (D, 200×) assays. ***P < 0.001; Scale bar = 150 μm. (TIF 19013 kb

Additional file 8: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Figure S3. The pairwise comparison matrix used in the AHP model. The weighting coefficients of the criteria layer were calculated on the basis of the maximum eigenvalue using the sum-product method. (TIF 481 kb

Additional file 6: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Table S4. Gene information on the Human Glucose Metabolism Array. (DOCX 19 kb

Additional file 2: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Table S2. Antibodies used in Western blot analysis. (DOCX 21 kb

Additional file 7: of Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Figure S2. Functions of the differentially expressed genes in glucose and glycogen metabolism. These genes included HK2, PDP2, G6PD, PGK1, PHKA1, PYGL, PDK1, and PKM2. (TIF 1108 kb